{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:30:09Z","timestamp":1775885409514,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117977","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:57:37Z","timestamp":1753113457000},"page":"117977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["SGLT2 inhibitors in translational medicine: A paradigm shift for diabetes and heart health"],"prefix":"10.1016","volume":"298","author":[{"given":"Ritu","family":"Soni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achal","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Vaishnav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4798-7151","authenticated-orcid":false,"given":"Sanmati Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.117977_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2023.100506","article-title":"Molecules and targets of antidiabetic interest","volume":"4","author":"Gawli","year":"2024","journal-title":"Phytomed. Plus"},{"key":"10.1016\/j.ejmech.2025.117977_bib2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2018.04.061","article-title":"Current anti-diabetic agents and their molecular targets: a review","volume":"152","author":"Kerru","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117977_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/XCE.0000000000000210","article-title":"Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data","volume":"9","author":"Heald","year":"2020","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2025.117977_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117977_bib6","first-page":"189","article-title":"American Diabetes Association 2010. Diagnosis and classification of diabetes mellitus","volume":"33","author":"Aranaz","year":"2023","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117977_bib7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2337\/diacare.19.8.827","article-title":"Parental history of diabetes in a population-based study","volume":"19","author":"Klein","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2025.117977_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113217","article-title":"Exploring the plant-derived bioactive substances as antidiabetic agent: an extensive review","volume":"152","author":"Rahman","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.117977_bib9","first-page":"S11","article-title":"Classification and diagnosis of diabetes","volume":"40","author":"Care","year":"2017","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117977_bib10","first-page":"443","article-title":"A comprehensive approach to type 2 diabetes mellitus\u2013A recommendation document","volume":"66","author":"Reyes-Garcia","year":"2019","journal-title":"Endocrinol. Diabetes Nutr."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117977_bib11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications","volume":"88","author":"Deshpande","year":"2008","journal-title":"Phys. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.117977_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diabres.2019.02.008","article-title":"Diabetes and Ramadan: a multicenter study in Algerian population","volume":"150","author":"Malek","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117977_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.afos.2016.02.001","article-title":"Type 2 diabetes mellitus and bone fragility: special focus on bone imaging","volume":"2","author":"Choi","year":"2016","journal-title":"Osteoporosis and Sarcopenia"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ecl.2013.06.005","article-title":"Complications of diabetes therapy","volume":"42","author":"Corathers","year":"2013","journal-title":"Endocrinol. Metabol. Clin"},{"issue":"14","key":"10.1016\/j.ejmech.2025.117977_bib16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"7258","key":"10.1016\/j.ejmech.2025.117977_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"Bmj"},{"key":"10.1016\/j.ejmech.2025.117977_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112523","article-title":"An exhaustive perspective on structural insights of SGLT2 inhibitors: a novel class of antidiabetic agent","volume":"204","author":"Bhattacharya","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117977_bib19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117977_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib21","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium\u2013glucose cotransporters: functional properties and pharmaceutical potential","volume":"11","author":"Sano","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ejmech.2025.117977_bib22","series-title":"Molecular Nutrition: Carbohydrates","first-page":"21","article-title":"Glucose transporters and their cellular form, role and function","author":"Navale","year":"2019"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","article-title":"Improved diabetic syndrome in C57BL\/KsJ\u2010db\/db mice by oral administration of the Na+\u2010glucose cotransporter inhibitor T\u20101095","volume":"132","author":"Arakawa","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117977_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3949\/ccjm.88a.20088","article-title":"The role of SGLT-2 inhibitors in managing type 2 diabetes","volume":"88","author":"Tsushima","year":"2021","journal-title":"Cleve. Clin. J. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117977_bib26","doi-asserted-by":"crossref","first-page":"F322","DOI":"10.1152\/ajprenal.1981.241.3.F322","article-title":"Differences in active and passive glucose transport along the proximal nephron","volume":"241","author":"Barfuss","year":"1981","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejmech.2025.117977_bib28","series-title":"PubChem Compound Summary for CID10453870, Ipragliflozin","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117977_bib29","series-title":"PubChem Compound Summary for CID44814423, Ertugliflozin","year":"2024"},{"key":"10.1016\/j.ejmech.2025.117977_bib30","series-title":"PubChem Compound Summary for CID9871420, Remogliflozin Etabonate","year":"2024"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117977_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.numecd.2006.05.006","article-title":"Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update","volume":"16","author":"Ceriello","year":"2006","journal-title":"Nutr. Metabol. Cardiovasc. Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coph.2005.01.002","article-title":"Cardiovascular complications in diabetes mellitus","volume":"5","author":"Sobel","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1742-1241.2008.01715.x","article-title":"Insulin detemir improves glycaemic control without weight gain in insulin\u2010na\u00efve patients with type 2 diabetes: subgroup analysis from the PREDICTIVETM study","volume":"62","author":"Dornhorst","year":"2008","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expet Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117977_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/14740330903081725","article-title":"Diabetes medications and body weight","volume":"8","author":"Mitri","year":"2009","journal-title":"Expet Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4093\/dmj.2014.38.4.261","article-title":"A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor","volume":"38","author":"Jung","year":"2014","journal-title":"Diabetes Metab. J."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1573406411666150105105529","article-title":"Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry","volume":"11","author":"Cai","year":"2015","journal-title":"Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117977_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117977_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117977_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/molecules29030741","article-title":"Phlorizin, an important glucoside: research progress on its biological activity and mechanism","volume":"29","author":"Ni","year":"2024","journal-title":"Molecules"},{"issue":"31","key":"10.1016\/j.ejmech.2025.117977_bib41","doi-asserted-by":"crossref","first-page":"14193","DOI":"10.1039\/D1NJ02510D","article-title":"Comprehensive structure\u2013activity relationship (SAR) investigation of C-aryl glycoside derivatives for the development of SGLT1\/SGLT2 dual inhibitors","volume":"45","author":"Xin","year":"2021","journal-title":"New J. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib42","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1573406411666150105105529","article-title":"Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry","volume":"11","author":"Cai","year":"2015","journal-title":"Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117977_bib43","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.bmcl.2016.03.065","article-title":"Modification on the O-glucoside of Sergliflozin-A: a new strategy for SGLT2 inhibitor design","volume":"26","author":"Cao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117977_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116033","article-title":"Discovery of remogliflozin etabonate: a potent and highly selective SGLT2 inhibitor","volume":"34","author":"Shimizu","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117977_bib45","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1016\/j.bmc.2012.09.037","article-title":"Structure\u2013activity relationship studies of 4-benzyl-1H-pyrazol-3-yl \u03b2-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia","volume":"20","author":"Fushimi","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117977_bib46","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ajoc.201700148","article-title":"trans\u2010Stilbene C\u2010glycosides: synthesis by a microwave\u2010assisted Heck reaction and evaluation of the SGLT\u20102 inhibitory activity","volume":"6","author":"Kumar Ponnapalli","year":"2017","journal-title":"Asian J. Org. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117977_bib47","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.tetlet.2012.02.062","article-title":"Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs","volume":"53","author":"Chen","year":"2012","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.117977_bib48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2012.06.053","article-title":"Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors","volume":"55","author":"Yao","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117977_bib49","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejmech.2019.07.032","article-title":"Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes","volume":"180","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117977_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carres.2015.10.011","article-title":"Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors","volume":"421","author":"Yan","year":"2016","journal-title":"Carbohydr. Res."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117977_bib51","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1016\/j.bmc.2010.04.088","article-title":"ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors","volume":"18","author":"Xu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2025.117977_bib52","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1016\/j.bmcl.2010.09.103","article-title":"Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors","volume":"20","author":"Lee","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1021\/ml100256c","article-title":"Synthesis and SAR of thiazolylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors","volume":"2","author":"Song","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117977_bib54","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1016\/j.bmc.2011.08.014","article-title":"Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents","volume":"19","author":"Lee","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117977_bib55","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.1021\/jm300884k","article-title":"Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"55","author":"Ohtake","year":"2012","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117977_bib56","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1016\/j.bmc.2013.08.067","article-title":"Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors","volume":"21","author":"Lin","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117977_bib57","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1016\/j.bmc.2014.04.036","article-title":"The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties","volume":"22","author":"Guo","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117977_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2016.02.053","article-title":"Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes","volume":"114","author":"Pan","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117977_bib59","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.bmcl.2018.04.070","article-title":"Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors","volume":"28","author":"Zhao","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117977_bib60","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.bmcl.2016.03.065","article-title":"Modification on the O-glucoside of Sergliflozin-A: a new strategy for SGLT2 inhibitor design","volume":"26","author":"Cao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.117977_bib61","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejmech.2017.11.019","article-title":"Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2","volume":"143","author":"Yuan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117977_bib62","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1016\/j.bmc.2018.06.017","article-title":"Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents","volume":"26","author":"Li","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117977_bib63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.bioorg.2018.11.006","article-title":"Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors","volume":"83","author":"Chu","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117977_bib64","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1016\/j.bmc.2013.05.048","article-title":"C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors","volume":"21","author":"Koga","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117977_bib65","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.bmc.2012.03.051","article-title":"Discovery of ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus","volume":"20","author":"Imamura","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117977_bib66","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1021\/jm901893x","article-title":"(1 S)-1, 5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment","volume":"53","author":"Kakinuma","year":"2010","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117977_bib67","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1016\/j.bmc.2013.03.067","article-title":"Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543","volume":"21","author":"Ikegai","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117977_bib68","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1016\/j.bmcl.2015.05.040","article-title":"C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents","volume":"25","author":"Ding","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117977_bib69","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1021\/jm200049r","article-title":"Discovery of a clinical candidate from the structurally unique dioxa-bicyclo [3.2. 1] octane class of sodium-dependent glucose cotransporter 2 inhibitors","volume":"54","author":"Mascitti","year":"2011","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib70","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acs.jmedchem.6b01134","article-title":"Targeting type 2 diabetes with C-glucosyl dihydrochalcones as selective sodium glucose co-transporter 2 (SGLT2) inhibitors: synthesis and biological evaluation","volume":"60","author":"Jesus","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117977_bib71","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00706-013-1053-0","article-title":"A facile synthesis of 6-deoxydapagliflozin","volume":"144","author":"Shi","year":"2013","journal-title":"Monatsh. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1573409914666181019165821","article-title":"In silico molecular docking study to search new SGLT2 inhibitor based on dioxabicyclo[3.2.1] octane scaffold","volume":"16","author":"Kumar","year":"2020","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.ejmech.2025.117977_bib73","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.6026\/973206300181044","article-title":"Insights from the molecular docking analysis of SGLT2 and FIMH to combat uropathogenicity","volume":"18","author":"Abdulaal","year":"2022","journal-title":"Bioinformation"},{"key":"10.1016\/j.ejmech.2025.117977_bib74","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3390\/molecules30102179","article-title":"Docking-based classification of SGLT2 inhibitors","volume":"30","author":"Mazoudji","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117977_bib75","doi-asserted-by":"crossref","first-page":"716","DOI":"10.56499\/jppres24.2104_13.3.716","article-title":"In silico discovery of potential sodium-glucose cotransporter-2 (SGLT-2) inhibitors from Smallanthussonchifolius (Poepp.) H. Rob. via molecular docking and molecular dynamics simulation approach","volume":"13","author":"Prasetiyo","year":"2025","journal-title":"J. Pharm. Pharmacogn. Res."},{"key":"10.1016\/j.ejmech.2025.117977_bib76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.56933\/Pharmaspire.2022.14218","article-title":"In silico studies for the identification of potential SGLT2 inhibitors","volume":"14","author":"Bhupal","year":"2022","journal-title":"Pharmaspire"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/dom.14599","article-title":"Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors, 2022","volume":"24","author":"Fadini","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2025.117977_bib78","doi-asserted-by":"crossref","first-page":"836849","DOI":"10.3389\/fphar.2022.836849","article-title":"Emerging roles of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in diabetic cardiovascular diseases: focusing on immunity, inflammation and metabolism","volume":"13","author":"Xie","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117977_bib79","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1111\/dom.15793","article-title":"Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: a counterfactual prediction model based on real-world data","volume":"26","author":"Siriyotha","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117977_bib80","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117977_bib81","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117977_bib82","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ejmech.2025.117977_bib83","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117977_bib84","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.ejmech.2025.117977_bib85","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117977_bib86","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib87","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117977_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:53:55Z","timestamp":1769622835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":89,"alternative-id":["S0223523425007421"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117977","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors in translational medicine: A paradigm shift for diabetes and heart health","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117977"}}